Skip to main content
. 2022 Apr 16;107(7):e2680–e2689. doi: 10.1210/clinem/dgac217

Table 5.

Convenience and overall satisfaction domains of TSQM-9 for subjects who transitioned to the TransCon hGH Auto-Injector (completed by caregiver)

Summary score Baseline
(reflects lonapegsomatropin vial/syringe or Genotropin pen)		 Transition week 6a
(reflects lonapegsomatropin via TransCon hGH Auto-Injector)		 Transition week 13a
(reflects lonapegsomatropin via TransCon hGH Auto-Injector)
Convenience (n = 158)
73.8 (15.6)		 (n = 142)
86.1 (13.7)		 (n = 111)
87.0 (14.8)
Global satisfaction (n = 157)
86.3 (14.5)		 (n = 142)
89.5 (12.6)		 (n = 111)
90.8 (12.5)

Data are given as mean (SD).

aTransition week × means approximately × weeks after transition from lonapegsomatropin via syringe/needle to lonapegsomatropin via TransCon hGH Auto-Injector.